Another weapon in our arsenal to fight Covid-19.

Medsafe has granted provisional approval for the Novavax vaccine Nuvaxovid.

It will join Pfizer and AstraZeneca to be the third vaccine approved by MedSafe.

Cabinet is yet to give final approval.

Novavax Vice-President Silvia Taylor told Heather du Plessis-Allan people trust their vaccine as it uses protein-based technology.

“We are finding that there is a sizeable part of the population around the world that is waiting for our vaccine, so we’re very excited about having it authorised in New Zealand.”

LISTEN ABOVE